Analysis of Lipid Nanoparticle Components Using an Agilent 6545XT AdvanceBio LC/Q-TOF

Importance of the Topic

Lipid nanoparticle (LNP) platforms have become essential for delivering mRNA and other biopharmaceuticals. The precise identity, ratio and purity of lipid components are critical quality attributes that influence formulation efficiency, stability and biological performance. Robust analytical methods for lipid profiling support formulation optimization and ensure consistency across research and manufacturing.

Study Objectives and Overview

This work describes the development and validation of a liquid chromatography coupled to quadrupole time-of-flight mass spectrometry method for simultaneous identification and quantification of key lipids in mRNA‐loaded LNPs. Using an Agilent 1290 Infinity II LC system and 6545XT AdvanceBio LC/Q-TOF, the method aims to deliver high resolution separation, accurate mass identification and reliable quantitation of ionizable lipids, helper lipids, cholesterol and PEGylated lipids.

Applied Methodology and Instrumentation

Sample Preparation and Standards

• LNPs were formulated by microfluidic mixing of an aqueous mRNA solution with an ethanol lipid blend at defined molar ratios.
• Lipid standards (SM-102, ALC-0315, DSPC, DOPE, DMG-PEG 2K, DOTAP and cholesterol) were prepared in methanol for calibration and method evaluation.

Chromatography and Mass Spectrometry

• Column: InfinityLab Poroshell 120 Phenyl-Hexyl, 2.1×50 mm, 1.9 μm.
• Gradient: seven-minute binary gradient from 100% aqueous methanol to 100% acetonitrile.
• Flow rate: 0.4 mL/min, column temperature: 55 °C.
• MS detection: positive electrospray ionization with dual AJS, extended dynamic range at 2 GHz, mass range 110–1700 m/z.
• Software: MassHunter Workstation for acquisition and Qualitative Analysis for data processing.

Main Results and Discussion

Separation and Identification

• Seven lipid species were baseline separated within seven minutes and accurately identified by exact mass (within 2.5 ppm).
• Elution order: cholesterol, DOPE, DOTAP, DSPC, SM-102, ALC-0315 and DMG-PEG 2K.

Reproducibility and Linearity

• Retention time RSD < 0.5% and peak area RSD < 1.5% over three injections demonstrated excellent precision.
• Calibration curves for cholesterol, DSPC, SM-102 and DMG-PEG 2K showed linear response (R2 ≥ 0.99) over four orders of magnitude on a logarithmic scale.

Stability Assessment

• LNPs stored after lyophilization retained target molar ratios of SM-102, DSPC, DMG-PEG 2K and cholesterol.
• Non-lyophilized samples exhibited significant lipid degradation, underscoring the importance of formulation and storage conditions for lipid integrity.

Benefits and Practical Applications

This LC/Q-TOF method provides a fast and reliable tool for lipid profiling in LNP formulations. It supports:

• Quality control of lipid composition in research and manufacturing.
• Process development by tracking excipient stability under different conditions.
• Regulatory compliance with quantifiable data on critical quality attributes.

Future Trends and Potential Applications

Advancements may include:

• Automation of sample preparation and data analysis for high-throughput screening.
• Extension to novel ionizable lipids and functionalized PEG-lipids.
• Integration with orthogonal techniques such as ion mobility or native mass spectrometry for detailed structural characterization.
• Application to other nanoparticle platforms and therapeutic modalities.

Conclusion

An Agilent 1290 Infinity II LC system coupled to a 6545XT AdvanceBio LC/Q-TOF has been demonstrated as an effective platform for the rapid, precise and accurate analysis of LNP lipid components. The method exhibits excellent separation, linearity and reproducibility, and is well suited for formulation development and quality control of mRNA based nanoparticle therapeutics.

References

• Verma M, Ozer I, Xie W, Gallagher R, Teixeira A, Choy M. The Landscape for Lipid-Nanoparticle-Based Genomic Medicines. Nat Rev Drug Discov. 2023;22:349–350.
• Cárdenas M, Campbell RA, Arteta MY, Lawrence MJ, Sebastiani F. Review of Structural Design Guiding the Development of Lipid Nanoparticles for Nucleic Acid Delivery. Curr Opin Colloid Interface Sci. 2023;66:101705.
• Albertsen CH, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The Role of Lipid Components in Lipid Nanoparticles for Vaccines and Gene Therapy. Adv Drug Deliv Rev. 2022;188:114416.
• Hassett KJ, et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2012;15:1–11.